Research advances in calcitonin gene-related peptides in treatment of migraine

VernacularTitle:降钙素基因相关肽类药物治疗偏头痛的研究进展
Author: Zhuo HAN ^{1
,

2} ; Dongjun WAN ; Dandan MA
Author Information

1. 西北民族大学医学院,甘肃兰州 730030
2. 中国解放军联勤保障部队第九四〇医院神经内科,甘肃兰州 730050
Keywords: Calcitonin gene-related peptide; Migraine; Monoclonal antibodies; Small-molecular receptor antagonists; Clinical trial
From: Journal of Apoplexy and Nervous Diseases 2024;41(7):604-610
CountryChina
Language:Chinese
Abstract: Migraine is a common type of primary headache worldwide,and its high morbidity and disability rates have brought heavy burden to individuals and society,thereby requiring preventive and acute treatment.Previous thera-peutic strategies for migraine include traditional analgesics and triptans,which are mainly used to relieve pain and reduce accompanying symptoms,but long-term administration of such drugs may lead to medication overuse headache.In recent years,new drugs targeting calcitonin gene-related peptide(CGRP)and its receptors have shown a promising future in the preventive treatment of migraine and the treatment of migraine in the acute stage,such as monoclonal antibodies and small-molecular receptor antagonists,and in addition,they also can be used in patients who have no response to various pharma-cotherapies.This article reviews the recent advances in CGRP drugs in the treatment of migraine.